在目前的工作中,我们描述了4-咪唑并[2,1 - b ]噻唑-1,4-二氢吡啶类重点文库的合成,表征和神经保护作用的评估。此外,在心脏组织和血管平滑肌中对新的二氢吡啶进行了功能性体外测定,以确定它们在抵消神经退行性变中的可能选择性。特别是,设计化合物所采用的策略涉及咪唑并[2,1- b ]噻唑核。观察到的性质表明,双环支架的C2和C6处的取代基能够影响心血管参数和神经保护活性。与硝苯地平相比,一组衍生物如化合物6表现出特别重要的神经保护作用。
Optimization of permethyl ningalin B analogs as P-glycoprotein inhibitors
作者:Zhen Wang、Iris L.K. Wong、Fu Xing Li、Chao Yang、Zhen Liu、Tao Jiang、Ting Fu Jiang、Larry M.C. Chow、Sheng Biao Wan
DOI:10.1016/j.bmc.2015.07.027
日期:2015.9
In the present study, a total of 9 novel permethyl ningalin B analogs have been synthesized and evaluated for their P-gp modulating activity in a P-gp overexpressed breast cancer cell line LCC6MDR. Among these derivatives, compound 12 with dimethoxy groups at rings A and B and tri-substitution at ring C with ortho-methoxyethylmorpholine, meta-bromo and para-benzyloxy groups displays the most potent P-gp modulating activity with EC50 of 423 nM to reverse paclitaxel resistance. It is non-toxic towards L929 fibroblast with IC50 greater than 100 mu M and with selective index greater than 236. Its mechanism to reverse P-gp mediated drug resistance is by virtue of inhibiting transport activity of P-gp, restoring intracellular drug accumulation and eventually chemosensitizing the cancer cells to anticancer drug again. Moreover, compound 12 showed better solubility (405 ng/mL) than hit compound 1 in phosphate buffer (pH 4.0). In summary, our study demonstrates that permethyl ningalin B derivative 12 is non-toxic and efficient P-gp inhibitor that is a potential candidate to be used clinically to reverse P-gp mediated cancer drug resistance. (C) 2015 Elsevier Ltd. All rights reserved.
BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2